Recent Company News

• 05:19 AM ET Aug 29, 2025
  

  Opthea reports FY NPAT ($162.8M) vs year-ago ($220.2M) -- Appendix 4E (A$0.60, 0.00)

• 06:55 PM ET Aug 18, 2025
  

  Opthea reaches DFA settlement; DFA investors to be issued 9.99% equity with no subscription payment and a one-time payment of $20M (A$0.60, 0.00)

• 06:33 PM ET Jul 29, 2025
  

  Opthea reports Q4 net cash used in operating activities ($53.5M) - Appendix 4C (A$0.60, 0.00)

• 06:47 PM ET Jun 01, 2025
  

  Opthea provides corporate update; four board members to depart effective 2-Jun (A$0.60, 0.00)

• 07:00 PM ET Apr 29, 2025
  

  Opthea reports Q3 net cash used in operating activities ($32.4M) - Appendix 4C (A$0.60, 0.00)

• 07:27 PM ET Apr 09, 2025
  

  Opthea to reduce workforce by ~65% following negative trial results (A$0.60, 0.00)

• 04:37 PM ET Apr 01, 2025
  

  Opthea downgraded to sell from buy at Bell Potter (A$0.60, 0.00)

• 09:54 PM ET Mar 30, 2025
  

  Opthea shares to remain suspended (A$0.60, 0.00)

• 09:52 PM ET Mar 30, 2025
  

  Opthea reports ShORe Phase 3 trial fails to meet primary endpoint; Opthea and DFA Investors agree to terminate both COAST and ShORe trials (A$0.60, 0.00)

• 05:10 PM ET Mar 25, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market